Bio News
Celltrion received U.S. Food and Drug Administration (FDA) approval for the global Phase 3 trial plan for Zymfentra in rheumatoid arthritis.
The 52-week trial will enroll 296 patients with moderately to severely active rheumatoid arthritis.
Celltrion plans to demonstrate Zymfentra’s superiority over placebo based on the ACR50 response at Week 12.
Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
